Market cap
$61.9M

Neumora Therapeutics Inc. (NMRA) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for NMRA, including 3 SEC filings, 1 earnings update and 1 13D/G filing. The most recent was published Nov 16, 2026.

Financial highlights

Full financials
Net income, TTM
-$190.43M
Cash
$85.65M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

News · 26 weeks31+100%
2026-05-24: 62026-05-31: 02026-06-07: 02026-06-14: 42026-06-21: 02026-06-28: 02026-07-05: 02026-07-12: 02026-07-19: 02026-07-26: 22026-08-02: 02026-08-09: 32026-08-16: 112026-08-23: 02026-08-30: 02026-09-06: 02026-09-13: 02026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 02026-10-18: 02026-10-25: 12026-11-01: 02026-11-08: 02026-11-15: 4
2026-05-242026-11-15
Mix1290d
  • SEC Filings5(42%)
  • Insider5(42%)
  • Earnings1(8%)
  • 13D/G1(8%)
Activity · 52 weeks6426 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

NMRA FAQ

9 questions
  • What is the latest news on NMRA?
    In the last 30 days Quantisnow tracked 5 wire items for NMRA: 3 SEC filings, 1 earnings update and 1 13D/G filing. The most recent was published on November 16, 2026.
  • Is NMRA profitable?
    No. Neumora Therapeutics Inc. reported a net loss of $190.43M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does NMRA have?
    Neumora Therapeutics Inc. reported $85.65M in cash and cash equivalents and $113.30M of debt on its most recent balance sheet in SEC filings.
  • Where does NMRA stock trade?
    Neumora Therapeutics Inc. (NMRA) is listed on NASDAQ.
  • What sector and industry is NMRA in?
    Neumora Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • When did Neumora Therapeutics Inc. go public?
    Neumora Therapeutics Inc. (NMRA) completed its IPO in 2023.
  • What are analysts saying about NMRA?
    Across the last 8 analyst actions on Neumora Therapeutics Inc., there were 3 upgrades and 2 downgrades. The most recent action was from H.C. Wainwright: Buy with a $7.00 price target on 2026-06-16.
  • What companies are similar to NMRA?
    Notable peers in the same industry include RLMD (Relmada Therapeutics Inc.), ANRO (Alto Neuroscience Inc.), VNDA (Vanda Pharmaceuticals Inc.), AXSM (Axsome Therapeutics Inc.). Compare NMRA side-by-side with any of them on Quantisnow.
  • How can I track NMRA on Quantisnow?
    Quantisnow aggregates Neumora Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NMRA to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change